Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
- 28 February 2011
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (1), 38-43
- https://doi.org/10.3816/clml.2010.n.120
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaHaematologica, 2010
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia, 2009
- Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myelomaBlood Reviews, 2009
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaThe New England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaThe New England Journal of Medicine, 2007
- Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.Blood, 2007
- Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With CancerJAMA, 2006
- International uniform response criteria for multiple myelomaLeukemia, 2006
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998